Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept in Very Low Vision Wet AMD
CTR20131281Phase 2Completed
- Sponsor
- Chengdu Kanghong Biotechnology Co., Ltd.
- Start
- Jun 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of conbercept in exudative macular degeneration, sponsored by Chengdu Kanghong Biotechnology Co., Ltd. Primary endpoint: Proportion of subjects with BCVA ≥19 letters. Started Jun 2014; status: completed.
02
Drugs
conbercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20131281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131281.